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To the Editor,
We read the letter by Battaggia et al. [1] commenting our 
systematic review and meta-analysis on the association 
between hyperuricemia (HU) and coronary heart disease 
(CHD) incidence and mortality [2], and we thank the 
authors for giving us the opportunity to better explain and 
emphasize some important points of our work.
In our study, we updated the literature search and 
reviewed available observational prospective cohort 
studies about the relationship between HU and future 
CHD incidence and mortality in the CHD-free population 
that fulfilled well-defined selection criteria, including 
the explicit definition of the urate threshold above which 
the risk, if present, became clinically important. Regard-
ing the CHD incidence, which is the outcome preferen-
tially considered by Battaggia et  al., our meta-analysis 
showed a slight but significant (p = 0.003) increase of CHD 
risk [risk ratio (RR) = 1.206 (1.066–1.364)] in hyperurice-
mic subjects, becoming more evident in hyperuricemic 
women [RR = 1.446 (1.323–1.581)]. Based on these results, 
 Battaggia et  al. conclude that the main message of our 
study was that the treatment of HU should be included 
in the therapeutic strategies to reduce the CHD risk. We 
would like to clarify, however, that we never wrote this 
recommendation anywhere in the text. On the contrary, 
we believe that, for many reasons, the message of our 
paper is just opposite to what these authors have deduced.
First, it should be noted that the primary studies 
included in our meta-analysis are all observational, 
meaning that they are designed to investigate risk 
factors (defined as distinct volume categories) and not 
interventions or the need for promoting therapeutic 
strategies [3]. Second, we clearly stated that further 
specifically designed trials are needed to confirm the 
meta-analysis outcome because of the low number of 
retrieved trials fulfilling inclusion criteria and the sig-
nificant heterogeneity found among them (I2 statistic, 
~65%). Finally, in our opinion, our results have the merit 
to revaluate down the stronger statistical significance 
obtained in some previous meta-analyses on the asso-
ciation between HU and future cardiovascular disease 
mortality, raising therefore further perplexity about a 
possible treatment focused on HU. If one wishes to find 
a practical indication from our results, they might just 
suggest promoting more surveillance in subjects with 
HU, mainly if women, through, e.g. diet modification 
without necessarily resorting to drugs.
Battaggia et al. evaluated our meta-analysis by using 
the AMSTAR checklist [4], obtaining a medium/low meth-
odological quality. In particular, they considered 4/11 
items fully satisfied, 3/11 not satisfied and 4/11 uncertain. 
As the AMSTAR questionnaire asks reviewers to answer 
“Yes”, “No”, “Can’t answer” or “Not applicable”, we are 
a little surprised about the final judgment because they 
declare uncertainty in answering to more than one-third 
of questions. It has been already reported that some 
items of AMSTAR are difficult to interpret and theoreti-
cally hinder an accurate assessment [5]. Furthermore, the 
reliability of AMSTAR checklist as a tool to assess quality 
of systematic reviews of observational studies is prone to 
several criticisms, and assessors should be aware of this 
as well as to consider that speculations on the need for 
primary prevention programs according to observational 
data may be useless [6]. Even if not explicitly mentioning 
AMSTAR checklist, we reported the poor applicability of 
some AMSTAR items to our meta-analysis. For instance, 
AMSTAR item 7 (critical appraisal of included studies) 
is difficult to apply in order to obtain the true methodo-
logical quality of primary studies included in our meta-
analysis [5]. As a matter of fact, there is no gold standard 
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for the critical appraisal of non-randomized studies, 
and thus it is difficult to provide any characteristics that 
should be covered to assess the methodological quality of 
these studies, particularly if resorting to an observational 
design [6]. This is relevant if we consider that Battaggia 
et al. declare our meta-analysis “very far from excellent” 
because of the lack of any (explicit) assessment of the 
validity of the included studies. Appropriately combin-
ing findings of retrieved studies (AMSTAR item 9) is also 
very challenging in doing meta-analysis from observa-
tional studies. Theoretically, randomized controlled trials 
(RCTs) provide unbiased estimate of the effect, whereas 
observational studies may not reflect the true effect for 
the presence of confounding factors and bias [7]. To over-
come this, we followed running recommendations and 
accordingly we pooled bias-adjusted results for each 
study instead [8].
Battaggia et  al. demonstrate through a metaregres-
sion that the association between HU and CHD tends 
to decrease by increasing the number of confound-
ers considered. Being aware about this problem, in our 
meta-analysis we selected the first RR value resulting 
statistically significant after adjustment for as many con-
founders as possible. Unfortunately, we found a very high 
heterogeneity among confounder adjustments in differ-
ent individual studies and this was clearly expressed in 
the paper as the main limitation [2]. Battaggia et al. claim 
that three of nine primary studies considered in our meta-
analysis were not adjusted for nutritional status, and 
therefore, they hypothesize that metabolic syndrome was 
not accounted for a high number of enrolled subjects. 
However, specific mention about the presence/absence of 
metabolic syndrome is lacking in the quoted papers and 
in none of them the information about metabolic syn-
drome is reported in tables showing baseline characteris-
tics of subjects or even in the text describing populations. 
On the other hand, it is important to highlight that some 
of the factors concurring to the definition of metabolic 
syndrome have been adjusted in these three papers (see 
Table 1 of our paper). Similarly, there were other factors 
not always considered as confounders in primary studies. 
To this regard, we reported the example of renal function 
that has been evaluated as confounder only in one study. 
It is note worthy that there are no main indications on 
how to deal with different adjustments in various obser-
vational studies. Regression models are generally used to 
account for confounding factors and bias, but they often 
fail in fully correcting for all biases [9]. Furthermore, 
understanding and assessing the quality of regression 
models is much more difficult in observational studies 
than in RCTs [10].
In conclusion, the position of Battaggia et  al. about 
the topic of HU as CHD risk factor is not far from ours. 
Many of the issues raised by these authors, including the 
lack of reliable clinical evidence able to support the use 
of urate-lowering drugs for preventing CHD events, were 
already addressed in our paper.
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